The company

The Organization

Scientific Founders

Thomas P. Stossel, MD (Founding Scientist, Director)
- American Cancer Society Professor of Medicine, Harvard Medical School
- Director, Translational Medicine Unit, Brigham & Women’s Hospital
- Member, National Academy of Sciences

Renowned Harvard clinician/researcher (mechanisms that enable cells to crawl & metastasize)
AB, Princeton University; MD Harvard Medical School

Po-Shun Lee, MD (Founding Scientist)

Instructor in Medicine at Harvard Medical School
Attending, Pulmonary & Critical Care Division, Brigham & Women’s Hospital
Gelsolin assay studies & pre-clinical studies of gelsolin in various animal models
BA, Johns Hopkins University; MD University of Pennsylvania

Executive Team

James W. Fordyce (Chairman)
- Managing Partner, MEDNA Partners (private advisory firm)
- Chairman Emeritus of the Board of the Albert & Mary Lasker Foundation

Founding General Partner, Prince Ventures
MBA, Harvard Bus. School; MA, Magdalen College, Oxford University and BA, University of Pennsylvania

Board of Directors

James W. Fordyce (Chairman)
Gerald Chan- Morningside Venture
Scott Coleridge- Morningside Venture
Ashleigh Palmer
Thomas P. Stossel, MD

Investor

The lead investor in CBC is Morningside Venture (www.morningside.com). Morningside is a diversified investment management group founded in 1986 by the Chan family of Hong Kong. It is engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. Morningside Group was one of the earliest institutional investors in China's internet industry and in recent years has been an active investor in China's emerging biotechnology sector.

The Company’s History

Critical Biologics Corporation, based in Cambridge, MA, and Hunterdon County, NJ, was founded in 2004 and began fund raising in 2006 with the strategic intent to develop and commercialize diagnostics and therapeutics that predict and regulate inflammatory responses to life-threatening diseases. Initially, CBC's initial focus is on a theranostic approach to treat critical care patients with low plasma gelsolin levels at high risk of life-threatening complications. Gelsolin was discovered by Dr. Tom Stossel, American Cancer Society Professor of Medicine at Harvard Medical School and Director of the Translational Medicine Division and Senior Physician in the Hematology Division at Brigham & Women’s Hospital. In October 2006, CBC entered into an agreement with Brigham & Women’s Hospital to license technology and intellectual property pertaining to the therapeutic and diagnostic use of plasma gelsolin to predict and preemptively treat a variety of medically and economically important conditions.